Removal of ahiminoxamine and ferrioxamine by charcoal hemoperfusion and hemodlalysis. We studied the removal of aluminoxamine (MO) and ferrioxamine (FO) by (i) hemoperfusion/hemodialysis using an AluKart in combination with either a Cuprophan F-120 or a Hemophan' FH-l60 membrane, or (ii) hemodialysis with a high-flux F-60 polysulfone membrane. The same six dialysis patients underwent in a random order dialysis by the three set-ups after i.v. infusion of 30 mg/kg of desferrioxamine (DFO) during the last half an hour of the preceding dialysis session. The mean sri plasma MO and FO clearances of the AluKart" combined with either a F-120 or FH-160 membrane were 194.3 25.8 mI/mm (AIO) and 164.2 41.3 ml (FO) at the start of dialysis declining to respectively 76.6 27.3 and 68.5 42.6 mI/mm at the end of dialysis. With a high-flux dialysis membrane the intra-dialytic plasma clearance remained constant at 81.5 6.8 mI/mm for MO and 60.0 2.8 mI/mm for FO. In the presence of an AluKart" combined with a FH-160 up to 84 27% and 84 19% of the available AlO and FO could be removed during a four-hour hemoperfusion/hemodialysis session. During the first hour of dialysis, respectively 59 and 58% of the total amount of AIO and FO extracted by the AluKart" was removed compared to only 9 and 16% during the last hour. We conclude that the combined use of hemoperfusion/hemodialysis is highly effective followed closely by a high-flux F-60 membrane in the removal of AIO and FO and in combination with low (5 to 10mg/kg) DFO doses, may reduce the risk for side effects that have been associated with these compounds.
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Aluminum (Al) accumulation in hemodialysis patients can result in Al-induced bone disease, microcytic anemia and exceptionally in encephalopathy [1] . Recently it was found that this element may also be responsible for an insufficient response to erythropoietin treatment observed in some dialysis patients [2] . In 1980, Ackrill et al [3] used desferrioxamine (DFO), an iron (Fe) and Al chelating agent, in the treatment of patients with Al-overload/toxicity. Some studies were done dealing with the effect of DFO administration on the evolution of the intradialytic plasma Al levels in the presence of different types of dialyzers either or not combined with a charcoal hemoperfusion cartridge. Using a polysulfone dialyzer, Molitoris et al [4] observed a higher Al removal after DFO compared to a Cuprophan" membrane. McCarthy et al [5] studied the in vitro and
Received for publication May 24, 1991 and in revised form November 6, 1991 Accepted for publication November 8, 1991 © 1992 by the International Society of Nephrology in vivo characteristics of a coated charcoal hemoperfusion column in the removal of Al in the presence of DFO. The total plasma Al clearance with the combined hemodialysis/hemoperfusion device was higher than that obtained with the dialyzer alone. Weiss et al [6] , after comparing the Al removal in 17 dialysis patients, concluded that hemofiltration or a combination of hemodialysis and hemoperfusion should be used to remove Al in dialysis patients with signs of severe Al-accumulation/toxicity.
After DFO administration in renal failure, ferrioxamine (FO) has a relatively long plasma half-life [7] . On the other hand, FO can function as a siderophore to Rhizopus which may cause mucormycosis a frequently fatal disease [8] . Inter-dialytic plasma albumin-oxamine (MO) levels are stable and may be increased at even low DFO doses [7] . Exacerbation of aluminum encephalopathy after treatment with desferrioxamine has been reported [9] . The exact mechanism is unknown but is theorized to be due to either redistribution of aluminum mobilized by DFO into the brain or to the ability of the AIO complex to cross the blood/brain barrier. The role of AlO and FO in the development of other side effects is unknown. Thus, effective removal of these compounds, in addition to the use of an optimal DFO dose [7] is mandatory in order to develop an adequate and safe DFO treatment. In view of this, we studied the removal of both AlO and FO from the extracellular compartment by charcoal hemoperfusion and three dialyzer types (Cuprophan'. HemophanR, and polysulfone). Aluminoxamine and FO were measured using a recently developed method [101.
Methods

Patients
Six dialysis patients (3 men, 3 women), aged between 38 and 60 years, were in a random order and with a time interval of at least two weeks assigned to each of the following setups.
Hemoperfusion/hemodialysis. Hemoperfusion with AluKart'1 (National Medical Care (NMC), Dublin, Ireland) was used in combination with conventional dialysis using either a standard Cuprophan' membrane, type Focus F-120 (1.20 m2) (NMC) or a high-efficiency Focus FH-160 (1.62 m2) Hemophan" membrane (NMC). Charcoal columns contained 80 grams of activated charcoal (Fig. 1) . Hemodialysis. Hemodialysis using a high-flux F-60 polysulfone dialyzer (Fresenius, Bad-Homburg, Germany) was used.
This study was approved by the Ethical Committee of the Sismanoglion General Hospital, Athens, Greece. Patients gave informed consent to participation. Patients were ambulant and in a stable clinical condition. Subjects with liver disease and/or dialysis dementia were excluded. Aluminum hydroxide therapy was stopped during the test period.
Studies were conducted on a Fresenius A 2008 C hemodialysis machine, using either bicarbonate (35 mmol/liter; 2 patients) or acetate dialysate (35 mmol/liter; 4 patients). The blood flow rate was adjusted to 250 ml per minute while the dialysate flow was set at 450 ml per minute. Mean SD ultrafiltration rates were 10.2 4.1; 11.8 3.9 and 9.2 3.0 ml (NS) per minute for the AluKartR/FH160; AluKart'/F-l2O and F-60, respectively. The classic two-needle system for vascular access was used. The post-dialysis body weight of the patients ranged between 46 and 90 kg (mean SD: 65 14.5 kg). Thirty mg/kg of DFO (Desferal, Ciba-Geigy, Basle, Switzerland) was administered intravenously during the last half hour of the dialysis session preceeding the test session. The harmonic mean and range of the plasma Al, AlO, Fe and FO levels before DFO, at the start of the test session (that is, 44 hours after DFO) and the post-DFO plasma Al increment are presented in Table 1 . The plasma Al increment was determined by making the difference between the plasma Al concentration of each patient before and 44 hours after (that is, 5 mm before the start of the test session) DFO administration. Out of these individual data, the harmonic mean (range) was determined.
Analytical procedures Blood samples were taken as previously described [10] . In brief, particular attention was paid to avoid contamination and every item used during sample taking was regarded and checked as a potential source of extraneous addition of Al and Fe. Sample taking was done before the start of the dialysis session during which DFO was administered, and five minutes before and 5, 30, 60, 120, 180 and 240 minutes after the start of the test sessions.
When the AluKartR was used samples were taken at the inlet (A) (Fig. 1 ) and the outlet (B) ( inlet dialyzer) of the charcoal column and at the outlet (C) of the dialyzer. With the polysulfone F-60 dialyzer, samples were taken at the inlet (B) and outlet (C) of the dialyzer. Dialyzer clearances for the different compounds were calculated according to the following formula:
Clearance (Cl) = CA-CV/CA x QB + UF.
Here, CA and CV are the arterial and venous concentrations of the respective compounds (tmol/liter) while QB represents blood flow (ml/min) and UF the ultrafiltration rate (mllmin).
Because of the relatively small degree of ultrafiltration (± 10 ml per mm) no correction was made for differences between the blood flow at the in-and outlet of the dialyzer. Total AlO and FO removal was assessed as follows:
where i represents the number of sampling set points; (i = corresponding with the sample taken at zero time; that is, the start of the test dialysis session).
Assuming that AlO and FO are confined to the extracellular compartment [11] and that in renal failure this volume contributes to 20% of the total body weight, the total body burden (BB) of these compounds at the start of dialysis was estimated using the formula below:
Here, BW represents the patients' body weight after dialysis (kg), UFv corresponds with the total volume of ultrafiltration (kg) and CA is the arterial plasma concentration of the respective compounds at the start of dialysis.
Plasma Al and Fe were determined by electrothermal atomic absorption spectrometry using our previously reported methods [11, 12] . For the determination of AlO and FO we used an indirect Zeeman atomic absorption method [10] . Briefly, with the latter method AlO and FO are selectively extracted into benzyl alcohol. The Al and Fe concentration of these 1:1 
Statistics
Data are expressed as the mean SD (percentages of extraction, clearances) or as the harmonic mean (range) for the non-gaussion distributed data (plasma Al, AlO, Fe and EU levels, plasma Al increment and absolute amounts of Al, AlO and FO removed during dialysis). Statistical evaluation was carried out using the Wilcoxon rank sum test for matched pairs. A P value <0.05 was considered to be significant at a two-tailed level.
Results
A three-to fourfold increase in the plasma Al levels was noted 44 hours after administration of a 30 mg/kg DFO dose (Table 1 , Fig. 2A-C) . Plasma Fe at this time point had not changed significantly. Forty-four hours after DFO administration 80 10% of the plasma Al appeared as AlO. Regarding Fe, we noted that only 8.1 0.8% of the total plasma Fe was present as FO (Fig. 3) .
The evolution of the mean AlO and FO clearances obtained with the three set-ups are shown in Figure 4A -B. Using a F-fib polysulfone membrane plasma AlO and FO clearances remained stable at 81. 5 6.8 ml/min and 60.0 2.8 ml/min, respectively. In the presence of an AluKartR clearances of both AlO and EU at the start of dialysis were considerably greater, but, decreased rapidly during the first two hours of dialysis. AlO clearance with the FH-160 was significantly greater than that using the conventional F-120 CuprophanR membrane (P < 0.01). An important observation is that in all cases plasma AlO clearances tended (on the borderline of significance; P < 0.05) to be greater than those observed for FO. Considering a harmonic mean (range) post-DFO plasma AlO and FO concentration of 5.4 (3.0 to 11.9) and 1.1 (0.7 to 2.6) xmolfliter, respectively (Table 1) , the total amounts of AlO and FO removed during a dialysis session using the AluKart'/FH-160 device were 62.2 (30.4 to 144) and 16.3 (6.8 to 35.5) jxmol which corresponded to 1.68 (0.82 to 3.39) mg of Al and 0.91 (0.38 to 1.99) mg of Fe (Fig. 5) . Corresponding data using an A1uKart'/F-l20 or a polysulfone F-60 dialyzer were 1.52 (0.64 to 3.82) and 1.37 (0.87 to 1.86) mg of Al and 0.97 (0.53 to 3.4) mg and 0.46 (0.14 to 1.81) of Fe, respectively. The amounts of AlO and FO removed by the FH-160 and the F-120 dialyzer alone were significantly lower (P < 0.05) than those noted for the AluKartR alone or the F-60 polysulfone dialyzer (Fig. 5) .
We calculated that respectively 84 27%, 73 34% and 67 20% (NS) of the total AlO body burden was removed during a four-hour dialysis session in the presence of an A1uKartR/FH 160; AluKart'/F-l20 or the F-60, respectively. Corresponding data for FO were 84 19%; 69 28% and 63 22% (NS) ( Table 2 ). The contribution of the FH-160 and F-120 dialyzers in the total extraction of both AlO and FO never exceeded 30%.
The hourly elimination of AlO and FO is presented in Table  3 indicating that over 50% of the total amount of AlO and FO removed by the AluKart' was already extracted during the first hour of treatment, declining to maximally 20% during the last hour of dialysis.
Discussion
Aluminum accumulation/toxicity is a well recognized clinical problem in patients with end-stage renal disease. In the therapy of Al-overload/toxicity all potential sources of Al should be eliminated (appropriate water treatment, the use of parenteral fluids with negligible Al contamination, discontinuation or reduction of oral Al-containing phosphate binders) [13] . Although these preventive measures considerably reduce the incidence [14] and have, according to some authors [15, 161, a beneficial effect on the reversal of Al-induced encephalopathy, osteomalacia and anemia, they are ineffective to remove Al from the body.
We and others [11, 17] have previously shown that in the absence of DFO Al is not removed during a routine hemodialysis session. Until now, several studies have been conducted to investigate the removal of Al [4] [5] [6] [17] [18] [19] [20] and to a lesser extent Fe [21, 22] during dialysis after DFO. In this study: (i) the efficacy of a high-flux F-60 polysulfone dialyzer was compared to that of the hemoperfusion/hemodialysis device using the AluKartR in combination with either a Hemophan' FH-160 or Cuprophan' F-l20 dialyzer, and (ii) the removal and clearance of both the AlO and FO complexes was investigated in (iii) a paired fashion. Determination of the latter species instead of elemental Al and Fe is important with regard to side effects such as the development of mucormycosis [8, 23, 24] , ocular and auditory disturbances [25] and exacerbation of aluminum encephalopathy [9] , that have been associated to the formation of these compounds.
In the present study data on AlO and FO are based on a validated analytical method having great accuracy and precision [10] . Its low detection limits and high sensitivity were largely sufficient for the purpose of this study. Compared to other techniques, the method is not prone to interferences by pigments and drugs [26] , and does not require laborious procedures for purification and pretreatment of samples [27] . Plasma AlO clearances in the present study, obtained using a high-flux polysulfone F-60 membrane are in agreement with the data reported by Molitoris et al [4] showing plasma Al clearances to be around 80.5 7.5 mI/mm in the presence of a Fresenius high-flux Model F-80 dialyzer, and those of Aarseth and Ganss [201 reporting the plasma Al clearance of a F-60 membrane to be 34% of a 200 to 250 mI/mm blood flow. It is worthwhile to note that the plasma AlO clearances obtained using the polysulfone F-60 membrane were significantly higher than those using the FH-160 HemophanR dialyzer, which in turn were significantly greater than those noted with a F-120
CuprophanR membrane. Our data on the plasma AlO clearance determined using the latter dialyzer are close to the figures reported for plasma Al by Muirhead et al (39.4 4.1 mlImin) [19] , Simon et al (40. 5 9.7 ml/min) [28] and Pierides and Pierce Myli (37.6 10.8) [29] . However, they are significantly greater than the data reported by Molitoris et al ( [17] . These discrepancies are most likely due to the fact that in the latter studies ultrafiltration rates have not been taken into account. In contrast to some [5, 6] we placed the AluKart' proximally to the dialyzer. This set up has the advantage that a better temperature equilibrium, and electrolyte correction is obtained in the blood leaving the set up. The counter argument that the latter set up leads to a more rapid saturation of the cartridge is not valid, since the evolution of the plasma AlO clearances observed by us is identical to that reported by others [5, 6] who inserted the AluKart' post-dialyzer. Moreover, with the set up used in the present study, plasma AlO clearances by the AluKartR, determined at the start as well as at the end of dialysis, were considerably higher than the plasma Al clearances reported using the AIuKart' positioned distal to the dialyzer [5, 61. We calculated that for a post-DFO plasma Al increment of 4.9 jimoL'liter (131 jig/liter), up to 1.68 mg of Al could be removed during a dialysis session when the AluKart' was used in combination with a FH-160 membrane. The net removal for a comparable plasma Al increment was 1.37 mg when the F-60 polysulfone dialyzer was used. These figures fit well in the linear regression curve; Y = 13.8X + 42 (r: 0.9640; N = 27), we previously [11] established by correlating the plasma Al decrease during a four hour dialysis session (X) with the total amount of Al found in the collected dialysate (Y).
Our data indicate that the AluKartR/hemodialyzer device and to a less extent the use of a high-flux polysulfone dialyzer are effective for the removal of Al and may considerably shorten the duration of DFO therapy for Al overload. The high efficacy of the hemoperfusion/hemodialysis combination in the removal of MO and FO must, notwithstanding its saturation effect, be ascribed to the A1uKart'.
The good performance of the F-60 polysulfone dialyzer is striking with regard to the data in the literature showing that with a conventional CuprophanR membrane [4, 30] only 25 to 30% of the DFO chelated Al is extracted during a conventional dialysis session. From a chemical point of view Al and Fe exhibit a number of similar characteristics. However, we noted a conspicuous discrepancy with regard to their chelation to DFO. Although in vitro, Fe has a much greater affinity to DFO than Al [31, 32] only a small fraction (< 10%) of the total plasma Fe was present as FO at the start of dialysis 44 hours after DFO administration whereas 80% of the total plasma Al was DFO-bound. This indicates that the in vitro affinity of a chelator for a certain metal is not a reliable index for the in vivo chelation efficacy. In fact, these observations furthermore indicate that in contrast to Al, hemodialysis either or not in combination with hemoperfusion is not effective to lower the Fe status of hemosiderotic patients. Therefore, the reduction of the plasma ferritin levels [221 or the decrease in the liver Fe content [33] of hemodialysis patients after DFO must also be due to intrahepatic iron chelation followed by biliary elimination of FO during the interdialytic period [7] , in addition to the removal of the element during dialysis. When DFO is administered for Al overload formation of FO occurs. In dialysis patients, exposure to the latter compound has been associated with the development of severe and often fatal infections with non-siderophore producing microorganisms. Recently, Van Cutsem and Boelaert [24] demonstrated an enhanced growth of two particular Rhizopus strains in the presence of FO concentrations as low as those encountered in dialysis patients 44 hours after DFO. Aluminoxamine has been associated with a deterioration of a patient's encephalopathic status even at low DFO doses [34] . The role of AlO and FO in the development of side effects other than the above is not yet clear. Therefore, because of its high efficacy in the removal of 
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AluKart®/FH-160 AluKart!sIF-120 Fresenius F-60 I both the FO-and AlO-complexes, the hemoperfusion/hemodialysis setup and to a lesser extend the use of a high-flux polysulfone dialyzer will limit the exposure of dialysis patients to these compounds and in combination with low DFO doses, will reduce the putative risk for side effects, thus providing a safer therapy for Al overload.
